The Use of Topical Antibiotics Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data in 2017

Nakanishi, Tomoko; Inose, Ryo; Kusama, Yoshiki; Ishikane, Masahiro; Kajihara, Toshiki; Yahara, Koji; Sugai, Motoyuki; Ohge, Hiroki; Ohmagari, Norio

doi:10.7883/yoken.jjid.2021.450

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have examined data from the NDB (14-16) and NDB Open Data (17, 18). The need for informed consent was waived because the data published by NDB Open Data are anonymized and publicly available.…”

Section: Methodsmentioning

confidence: 99%

Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database

Sako

Masui

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Both physicians and patients are proactive towards managing seasonal influenza in Japan and six drugs are approved. We aimed to clarify the status of anti-influenza drug use by analyzing real-world data. Methods: This retrospective study analyzed open data from the National Database of Health Insurance Claims and Specific Health Checkups, which covers most claims data from national health insurance. We estimated the annual number of patients prescribed anti-influenza drugs, their age and sex distribution, drug costs, and regional disparities for the period 2014-2020. Results: For 2014-2019, an estimated 6.7-13.4 million patients per year were prescribed anti-influenza drugs, with an annual cost of 22.3-48.0 billion JPY (Japanese Yen). In addition, 21.1-32.0 million rapid antigen tests were performed at a cost of 30.1-47.1 billion JPY. In 2017, laninamivir was the most frequently prescribed anti-influenza drug (48%), followed by oseltamivir (36%), while in 2018, the newly introduced baloxavir accounted for 40.8% of prescriptions. After the emergence of COVID-19, the number of patients prescribed anti-influenza drugs in 2020 dropped to just 14,000. In 2018, 37.6% of prescriptions were for patients aged < 20 years compared with 12.2% for those aged ≥ 65 years. Prescriptions for inpatients accounted for 1.1%, and the proportion of prescriptions for inpatients increased with age. Male were more likely than female to be prescribed anti-influenza drugs for inpatient. Conclusions: Based on our clarification of how influenza is clinically managed in Japan, future work should evaluate the clinical and economic aspects of proactively prescribing anti-influenza drugs.

show abstract

Section: Methodsmentioning

confidence: 99%

Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database

Sako

Masui

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several studies have examined data from the NDB [15][16][17] and NDB Open Data [18,19]. The need for informed consent was waived because the data published by NDB Open Data are anonymized and publicly available.…”

Section: Plos Onementioning

confidence: 99%

Prescription of anti-influenza drugs in Japan, 2014–2020: A retrospective study using open data from the national claims database

Sako,

Gu,

Masui

et al. 2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Both physicians and patients are proactive towards managing seasonal influenza in Japan and six drugs are approved. Although many countries have national influenza surveillance systems, data on nationwide prescription practices of anti-influenza drugs are lacking. Therefore, we aimed to clarify the status of anti-influenza drug use in Japan by analyzing real-world data. Methods This retrospective study analyzed open data from the National Database of Health Insurance Claims and Specific Health Checkups, which covers most claims data from national health insurance. We estimated the annual number of patients prescribed anti-influenza drugs, which drugs they were prescribed, the patients’ age and sex distribution, drug costs, and regional disparities for the period 2014–2020. Results For 2014–2019, an estimated 6.7–13.4 million patients per year were prescribed anti-influenza drugs, with an annual cost of 22.3–48.0 billion JPY (Japanese Yen). In addition, 21.1–32.0 million rapid antigen tests were performed at a cost of 30.1–47.1 billion JPY. In 2017, laninamivir was the most frequently prescribed anti-influenza drug (48%), followed by oseltamivir (36%), while in 2018, the newly introduced baloxavir accounted for 40.8% of prescriptions. After the emergence of COVID-19, the estimated number of patients prescribed anti-influenza drugs in 2020 dropped to just 14,000. In 2018, 37.6% of prescriptions were for patients aged < 20 years compared with 12.2% for those aged ≥ 65 years. Prescriptions for inpatients accounted for 1.1%, and the proportion of prescriptions for inpatients increased with age, with men were more likely than women to be prescribed anti-influenza drugs while hospitalized. Conclusions Based on our clarification of how influenza is clinically managed in Japan, future work should evaluate the clinical and economic aspects of proactively prescribing anti-influenza drugs.

show abstract

“…Additionally, data on medical expenses that are not covered by insurance and uninsured persons' data are not included in the NDB data [21]. Numerous studies have been carried out using the NDB's aggregate data which are publicly accessible as open data [14,22,23].…”

Section: Outcome Variablementioning

confidence: 99%

Regional difference in multi-psychotropic drug prescription in Japan and its associated factors: an ecological study using national health insurance claims data

Okui

Nakashima

2023

Res Health Serv Reg

View full text Add to dashboard Cite

Background In Japan, regulations preventing the prescriptions of various types of psychotropic drugs have become stricter in recent years. However, the areas where multi-psychotropic drug prescriptions are common and the geographic factors that contribute to the regional difference, have not been studied. In this study, we used data from all claims in Japan to examine regional differences in the prescription for multi-psychotropic drugs using an ecological study. Methods The National Database of Health Insurance Claims and Specific Health Checkups of Japan Open data in 2019 were used. The outcome was the number of prescriptions for four or more different types of anxiolytics and hypnotics as well as for three or more of the same kind of psychotropic drugs (any one of anxiolytics, hypnotics, antipsychotics, antidepressants) for outpatients in each area. Among the 335 secondary medical areas in Japan, the data on 331 areas were used in the analysis. The standardized claim ratio (SCR), an indicator of the number of this multi-psychotropic drug prescription, correcting for regional differences in distribution of population by age and sex, was calculated for each of the secondary medical areas. The spatial cluster detection technique was used to locate a cluster of high-SCR areas. Furthermore, factors associated with regional differences in the SCRs were examined by a spatial statistics model. Results North Japanese regions tend to have high SCRs, and 13 areas in Hokkaido were identified as the most likely cluster (cluster with the highest likelihood ratio) for multi-psychotropic drug prescription. Furthermore, a spatial regression analysis revealed that the proportion of people with lower educational levels, the total number of prescriptions per capita, and the number of physicians working in psychiatric departments per capita were statistically positively associated with the SCR for the prescription of multiple psychotropic drugs. Conclusions It was suggested that socioeconomic and medical characteristics of areas are related to the regional variation in the multi-psychotropic drug prescriptions, however, further research using individual-level data is required to confirm these results.

show abstract

The Use of Topical Antibiotics Based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data in 2017

Cited by 4 publications

References 20 publications

Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database

Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database

Prescription of anti-influenza drugs in Japan, 2014–2020: A retrospective study using open data from the national claims database

Regional difference in multi-psychotropic drug prescription in Japan and its associated factors: an ecological study using national health insurance claims data

Contact Info

Product

Resources

About